Trials / Completed
CompletedNCT03819855
External Validation of a Septic Arthritis Prognosis Score
External Validation of the RESAS (REnnes Septic Arthritis Score) Septic Arthritis Prognosis Score in an Acute Arthritis Cohort of Less Than 30 Days
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 244 (actual)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Observational study
Detailed description
Septic arthritis is a diagnostic emergency for acute arthritis because it is accompanied by an excess of mortality of 11% and frequent functional sequelae in about 50% of cases in the year. However, it remains rare with an estimated annual incidence of 1 to 5/100000, and a prevalence of about 10% in front of an acute arthritis table sent to an emergency department. The diagnosis is based on the bacteriological culture which finds the presence of a microorganism within the joint. However, only 80% of septic arthritis is bacteriologically documented due to low inoculum, the presence of fragile bacteria (Neisseria sp) or especially untimely antibiotherapy prior to joint puncture. In addition, the bacteriological culture takes an average of 3 days to become positive, which may delay the implementation of appropriate antibiotic therapy. It is therefore essential that the clinician can rely on other clinical or biological parameters, reliable and fast for better diagnostic orientation. A first study: SYNOLACTATES showed the interest of the measurement of glucose and synovial lactate for the diagnosis of septic arthritis with very good performances. A RESAS score (REnnes Septic Arthritis Score) was constructed from these results to assess the likelihood of septic arthritis.
Conditions
Timeline
- Start date
- 2019-03-12
- Primary completion
- 2021-02-15
- Completion
- 2021-02-15
- First posted
- 2019-01-29
- Last updated
- 2021-03-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03819855. Inclusion in this directory is not an endorsement.